- Home
- OPAD vs ADAG Comparison
OPAD vs ADAG Comparison
Compare OPAD & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPAD | ADAG |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 90.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPAD | ADAG |
|---|---|---|
| Price | $1.28 | $2.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $1.88 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 8.0M | 70.9K |
| Earning Date | 02-23-2026 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $627,966,000.00 | $103,204.00 |
| Revenue This Year | N/A | $4,446.34 |
| Revenue Next Year | $8.25 | $30.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.91 | $1.30 |
| 52 Week High | $6.35 | $3.16 |
Technical Indicators
Market Signals| Indicator | OPAD | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 57.08 |
| Support Level | $1.21 | $1.69 |
| Resistance Level | $2.67 | $1.98 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 4.79 | 89.81 |
Price Performance
Historical ComparisonAbout OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.